Ascendis Pharma Added to Citi Focus List, Ionis Removed
Ionis Pharmaceuticals (NASDAQ:IONS) reported Q2 EPS of ($0.74), $0.13 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $134 million versus the...
By Natalie Grover LONDON (Reuters) -An interim analysis of AstraZeneca (NASDAQ:AZN) and partner Ionis Pharmaceuticals (NASDAQ:IONS)' eplontersen showed the experimental drug met...
Cathie Wood announced the upcoming closure of the ARK Transparency ETF Despite declines, investors continue to follow Wood’s holdings closely Consider 2 Ark Invest ETFs that...
USANA Health (NYSE:USNA) Sciences Inc. USNA is scheduled to report second-quarter 2020 results on Jul 21, aftermarketclose. The company flaunts a mixedearningssurprise history,...
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced that the European Commission has approved Givlaari (givosiran) for the treatment of acute hepatic porphyria (AHP) in patients...
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on our cardiovascular and neurology franchises. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for the treatment of patients of all ages with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients. The Company has over six medicines in Phase III studies for eight indications, which include Eplontersen (TTR), Olezarsen (ApoC-III), Donidalorsen (PKK), ION363 (FUS), Pelacarsen (Apo(a)) and Tofersen (SOD1). Its cardiovascular medicine in development includes Eplontersen, Olezarsen, Pelacarsen, ION449 (PCSK9), Fesomersen and IONIS-AGT-LRx.
|Average||47.33 (+3.80% Upside)|
|No. of Analysts||18|